GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Beneish M-Score

Protalix BioTherapeutics (FRA:PBDA) Beneish M-Score : -4.11 (As of Dec. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Protalix BioTherapeutics's Beneish M-Score or its related term are showing as below:

FRA:PBDA' s Beneish M-Score Range Over the Past 10 Years
Min: -5.84   Med: -1.99   Max: 3.28
Current: -4.11

During the past 13 years, the highest Beneish M-Score of Protalix BioTherapeutics was 3.28. The lowest was -5.84. And the median was -1.99.


Protalix BioTherapeutics Beneish M-Score Historical Data

The historical data trend for Protalix BioTherapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Beneish M-Score Chart

Protalix BioTherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.13 -1.61 -2.02 -1.50 -1.28

Protalix BioTherapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -1.28 -0.53 0.01 -4.11

Competitive Comparison of Protalix BioTherapeutics's Beneish M-Score

For the Biotechnology subindustry, Protalix BioTherapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protalix BioTherapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Protalix BioTherapeutics's Beneish M-Score falls into.



Protalix BioTherapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Protalix BioTherapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3347+0.528 * 2.0708+0.404 * 1.1165+0.892 * 0.706+0.115 * 0.8708
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3343+4.679 * -0.295576-0.327 * 0.844
=-4.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was €1.98 Mil.
Revenue was 16.181 + 12.517 + 3.448 + 9.616 = €41.76 Mil.
Gross Profit was 8.635 + 3.733 + 1.054 + 1.495 = €14.92 Mil.
Total Current Assets was €43.12 Mil.
Total Assets was €55.47 Mil.
Property, Plant and Equipment(Net PPE) was €9.27 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.18 Mil.
Selling, General, & Admin. Expense(SGA) was €12.24 Mil.
Total Current Liabilities was €21.82 Mil.
Long-Term Debt & Capital Lease Obligation was €3.76 Mil.
Net Income was 2.916 + -2.047 + -4.227 + -5.542 = €-8.90 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0.00 Mil.
Cash Flow from Operations was 3.699 + -3.354 + 3.853 + 3.297 = €7.50 Mil.
Total Receivables was €8.37 Mil.
Revenue was 9.693 + 32.374 + 8.955 + 8.134 = €59.16 Mil.
Gross Profit was 5.109 + 26.7 + 6.074 + 5.872 = €43.76 Mil.
Total Current Assets was €68.04 Mil.
Total Assets was €82.05 Mil.
Property, Plant and Equipment(Net PPE) was €9.93 Mil.
Depreciation, Depletion and Amortization(DDA) was €1.08 Mil.
Selling, General, & Admin. Expense(SGA) was €12.99 Mil.
Total Current Liabilities was €40.63 Mil.
Long-Term Debt & Capital Lease Obligation was €4.22 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.978 / 41.762) / (8.372 / 59.156)
=0.047364 / 0.141524
=0.3347

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(43.755 / 59.156) / (14.917 / 41.762)
=0.739654 / 0.357191
=2.0708

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (43.116 + 9.274) / 55.468) / (1 - (68.043 + 9.931) / 82.052)
=0.055491 / 0.0497
=1.1165

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=41.762 / 59.156
=0.706

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.078 / (1.078 + 9.931)) / (1.175 / (1.175 + 9.274))
=0.09792 / 0.112451
=0.8708

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(12.24 / 41.762) / (12.994 / 59.156)
=0.293089 / 0.219657
=1.3343

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3.763 + 21.822) / 55.468) / ((4.218 + 40.627) / 82.052)
=0.461257 / 0.546544
=0.844

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-8.9 - 0 - 7.495) / 55.468
=-0.295576

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Protalix BioTherapeutics has a M-score of -4.15 suggests that the company is unlikely to be a manipulator.


Protalix BioTherapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines